Aptevo files patent for Nectin-4 x PD-L1 dual-targeting backbone; new solid tumor strategy

Aptevo Therapeutics Inc.

Patent filing covers proprietary Nectin-4 x PD-L1 dual-targeting backbone for solid tumors.
Backbone may be adapted into radiopharmaceuticals, T-cell engagers, and immune-based therapies.
Strategy aims to enhance tumor targeting and anti-tumor immunity by targeting both Nectin-4 and PD-L1.
Filing strengthens IP portfolio and supports platform-driven approach for multiple assets and partnerships.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.